Legal & General Group Plc Cuts Position in Standard BioTools Inc. (NASDAQ:LAB)

Legal & General Group Plc trimmed its stake in Standard BioTools Inc. (NASDAQ:LAB) by 14.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 246,951 shares of the company’s stock after selling 40,593 shares during the period. Legal & General Group Plc owned 0.07% of Standard BioTools worth $432,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Royce & Associates LP boosted its position in shares of Standard BioTools by 136.8% in the 4th quarter. Royce & Associates LP now owns 1,455,503 shares of the company’s stock worth $2,547,000 after purchasing an additional 840,951 shares in the last quarter. Barclays PLC boosted its holdings in Standard BioTools by 13.2% in the third quarter. Barclays PLC now owns 3,228,360 shares of the company’s stock worth $6,231,000 after acquiring an additional 377,195 shares in the last quarter. GM Advisory Group LLC purchased a new stake in shares of Standard BioTools during the fourth quarter worth about $350,000. Bradley & Co. Private Wealth Management LLC acquired a new position in shares of Standard BioTools during the fourth quarter valued at about $314,000. Finally, Geode Capital Management LLC raised its position in shares of Standard BioTools by 2.3% in the 3rd quarter. Geode Capital Management LLC now owns 6,949,717 shares of the company’s stock valued at $13,415,000 after purchasing an additional 154,848 shares during the last quarter. 53.74% of the stock is currently owned by hedge funds and other institutional investors.

Standard BioTools Stock Performance

Standard BioTools stock opened at $1.16 on Wednesday. Standard BioTools Inc. has a fifty-two week low of $0.97 and a fifty-two week high of $2.74. The company has a market cap of $439.62 million, a PE ratio of -1.63 and a beta of 1.54. The business’s 50-day simple moving average is $1.15 and its two-hundred day simple moving average is $1.56.

Analyst Upgrades and Downgrades

Separately, KeyCorp lowered shares of Standard BioTools from an “overweight” rating to a “sector weight” rating in a research note on Thursday, February 27th.

Insider Activity at Standard BioTools

In related news, Director Casdin Partners Master Fund, L purchased 4,820,959 shares of the business’s stock in a transaction on Friday, February 28th. The shares were bought at an average cost of $1.06 per share, with a total value of $5,110,216.54. Following the transaction, the director now owns 58,846,780 shares of the company’s stock, valued at approximately $62,377,586.80. This trade represents a 8.92 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 53.10% of the stock is owned by insiders.

Standard BioTools Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.